Thiogenesis Therapeutics, Corp.
TTIPF
$0.6468
$0.086815.50%
OTC PK
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -86.53% | 47.12% | 38.74% | 26.53% | 33.17% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 50.17% | 70.07% | -59.91% | -46.46% | -53.76% |
| Change in Net Operating Assets | 131.13% | -67.89% | -661.35% | -47.79% | -8,014.06% |
| Cash from Operations | 60.95% | 24.86% | 17.21% | 21.02% | -128.83% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -93.84% | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -94.01% | -- | -- | -- |
| Foreign Exchange rate Adjustments | 82.98% | -169.59% | 123.61% | -126.47% | -729.41% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 49.57% | -108.44% | 19.92% | 19.59% | -77.51% |